Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 354979, 6 pages
Review Article

Ocriplasmin for Vitreoretinal Diseases

Retina Division, Jules Stein Eye Institute, University of California, Los Angeles, CA 90095, USA

Received 27 March 2012; Accepted 6 June 2012

Academic Editor: Lindsey A. Miles

Copyright © 2012 Irena Tsui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care.